EQL becomes Nordic representative for Qilu Pharmaceuticals
Qilu Pharmaceuticals (Qilu) has today received approval for Gefitinib Qilu tablet 250mg in Norway and the product is expected to be approved in Denmark and Sweden soon. Gefitinib Qilu is the first of currently seven pharmaceuticals in which EQL will act as a local representative for Qilu in the Nordic region. As a local representative, EQL buys, stocks and sells pharmaceuticals for Qilu in the Nordic region. Registration of the pharmaceuticals, on the other hand, is done by Qilu and they own all rights and have all obligations a registration brings with it from the Authorities.Qilu